Nasir Nisar

About

I am a pharmacologist by training with a Ph.D. in Pharmacology from the University of Kashmir, Srinagar, India. My doctoral research focused on evaluating the hepatoprotective potential of Salvia sclarea and Rumex nepalensis against chemically induced hepatocellular damage in experimental models. My research interests include in vitro and in vivo organ injury models, molecular toxicology, and cell signaling, with a particular focus on Nrf2-mediated antioxidant pathways in liver injury and oxidative stress. I have experience in HepG2 cell-based assays, Western blotting, phytochemical profiling, and histopathological evaluation. I have worked as a Junior Research Fellow at the Department of Pharmaceutical Sciences, University of Kashmir, and as a Visiting Research Fellow at CSIR-IIIM, Srinagar.

Employment

• University of Kashmir JRF
  2022 - 2024

Education

• University of Kashmir PhD
  2020 - 2025

Projects & Funding

Projects & funding information is unavailable.

Publications (11)

• Skin cancer: Eph/ephrin signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
  Proteomics: A Promising Approach for Cancer Research 2026 DOI: 10.1016/b978-0-443-23908-3.00013-7
  +Save
• Integrating in-silico and experimental validation approaches to unveil the therapeutic mechanism of naringenin against breast cancer
  Scientific Reports 2025 DOI: 10.1038/s41598-025-19931-6
  +Save
• Naringenin Inhibits Cellular Proliferation, Arrests Cell Cycle and Induces Pro‐Apoptotic Autophagy in MCF‐7 Breast Cancer Cells
  Journal of Cellular and Molecular Medicine 2025 DOI: 10.1111/jcmm.70747
  +Save
• Synergistic approaches: probiotics in combination with traditional antibiotics
  Probiotics against Antimicrobial Resistance 2025 DOI: 10.1201/9781032676951-8
  +Save
• Chemical Profiling and Hepatoprotective Potential of Chloroform–Methanolic Extract of Salvia sclarea L.: GC–MS Analysis and In Vivo Studies
  Chemistry & Biodiversity 2025 DOI: 10.1002/cbdv.202403496
  +Save
• Endometrial and placental dysfunction in recurrent pregnancy loss
  Reproductive Immunogenetics: A Molecular and Clinical Overview, Vol. 3 2025 DOI: 10.1016/b978-0-443-13617-7.00012-8
  +Save
• Immunotoxicogenomics: Moving from observation to prediction
  Immunotoxicogenomics 2025 DOI: 10.1016/b978-0-443-18502-1.00007-9
  +Save
• Flavonoids as promising molecules in the cancer therapy: An insight
  Current Research in Pharmacology and Drug Discovery 2024 DOI: 10.1016/j.crphar.2023.100167
  +Save
• Proteomics approaches in the identification of cancer biomarkers and drug discovery
  2023 DOI: 10.1016/B978-0-323-95072-5.00001-8
  +Save
• Comparison of survival and adverse effect profile in patients with esophageal cancer treated with the combination of carboplatin and paclitaxel vs. 5-flourouracil and cisplatin
  World Cancer Research Journal 2022 DOI: 10.32113/wcrj_20229_2399
  +Save